Calcimimetics in chronic kidney disease: Evidence, opportunities and challenges

Kidney International

Volumn 74, Issue 3, 2008, Pages 265-275

  Evenepoel, Pieter ^a  

^a UNIVERSITY HOSPITALS LEUVEN   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

1 (3 METHOXYPHENYL) N (3 PHENYLPROPYL)ETHYLAMINE; CALCIMIMETIC AGENT; CALCIUM; CINACALCET; FETUIN A; LIPOPROTEIN; N [3 (2 CHLOROPHENYL)PROPYL] 1 (3 METHOXYPHENYL)ETHYLAMINE; OSTEOPROTEGERIN; PARATHYROID HORMONE; PHOSPHATE; PHOSPHATE BINDING AGENT; PLACEBO; VITAMIN D DERIVATIVE;

BLOOD VESSEL CALCIFICATION; BONE BIOPSY; BONE DEMINERALIZATION; BONE DENSITY; BONE TURNOVER; CALCIUM BLOOD LEVEL; CARDIOVASCULAR RISK; CHRONIC KIDNEY DISEASE; CLINICAL FEATURE; CLINICAL TRIAL; DISEASE ASSOCIATION; DRUG COST; DRUG MECHANISM; DRUG METABOLISM; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSLIPIDEMIA; FRACTURE; GASTROINTESTINAL SYMPTOM; GLOMERULUS FILTRATION RATE; HEALTH CARE COST; HEMODIALYSIS; HUMAN; HYPERPARATHYROIDISM; HYPERTENSION; HYPOCALCEMIA; INTERMETHOD COMPARISON; KIDNEY CALCIFICATION; KIDNEY DYSFUNCTION; KIDNEY TRANSPLANTATION; MINERAL METABOLISM; MORBIDITY; MORTALITY; NONHUMAN; OSTEITIS FIBROSA; OSTEOMALACIA; OUTCOME ASSESSMENT; PARATHYROIDECTOMY; PRIORITY JOURNAL; RECURRENT DISEASE; RENAL OSTEODYSTROPHY; REVIEW; RISK ASSESSMENT; SECONDARY HYPERPARATHYROIDISM; SIDE EFFECT; TREATMENT OUTCOME; VASCULAR RESISTANCE;

EID: 47349115283     PISSN: 00852538     EISSN: 15231755     Source Type: Journal    
DOI: 10.1038/ki.2008.166     Document Type: Article

References (170)

1. Jadoul M, Albert JM, Akiba T et al. Incidence and risk factors for hip or other bone fractures among hemodialysis patients in the Dialysis Outcomes and Practice Patterns Study. Kidney Int 2006; 70: 1358-1366.
2. Torres A, Lorenzo V, Hernandez D et al. Bone disease in predialysis, hemodialysis, and CAPD patients: evidence of a better bone response to PTH. Kidney Int 1995; 47: 1434-1442.
3. Bro S, Olgaard K. Effects of excess PTH on nonclassical target organs. Am J Kidney Dis 1997; 30: 606-620.
4. Cunningham J. Are parathyroidectomies still appropriate in chronic dialysis patients? Semin Dial 2000; 13: 275-278.
5. Hruska KA, Saab G, Mathew S et al. Renal osteodystrophy, phosphate homeostasis, and vascular calcification. Semin Dial 2007; 20: 309-315.
6. 4 product, and parathyroid hormone with cardiac mortality risk in chronic hemodialysis patients. J Am Soc Nephrol 2001; 12: 2131-2138.
7. de Boer IH, Gorodetskaya I, Young B et al. The severity of secondary hyperparathyroidism in chronic renal insufficiency is GFR-dependent, race-dependent, and associated with cardiovascular disease. J Am Soc Nephrol 2002; 13: 2762-2769.
8. Block GA, Klassen PS, Lazarus JM et al. Mineral metabolism, mortality, and morbidity in maintenance hemodialysis. J Am Soc Nephrol 2004; 15: 2208-2218.
9. Young EW, Albert JM, Satayathum S et al. Predictors and consequences of altered mineral metabolism: the Dialysis Outcomes and Practice Patterns Study. Kidney Int 2005; 67: 1179-1187.
10. Slinin Y, Foley RN, Collins AJ. Calcium, phosphorus, parathyroid hormone, and cardiovascular disease in hemodialysis patients: the USRDS Waves 1, 3, and 4 Study. J Am Soc Nephrol 2005; 16: 1788-1793.
11. National Kidney Foundation. K/DOQI clinical practice guidelines for bone metabolism and disease in chronic kidney disease. Am J Kidney Dis 2003; 42: S1-S201.
12. Stevens LA, Djurdjev O, Cardew S et al. Calcium, phosphate, and parathyroid hormone levels in combination and as a function of dialysis duration predict mortality: evidence for the complexity of the association between mineral metabolism and outcomes. J Am Soc Nephrol 2004; 15: 770-779.
13. Drüeke TB. Treatment of secondary hyperparathyroidism of dialysis patients with calcimimetics as a valuable addition to established therapeutic means. Pediatr Nephrol 2005; 20: 399-403.
14. Rodriguez M, Nemeth E, Martin D. The calcium-sensing receptor: a key factor in the pathogenesis of secondary hyperparathyroidism. Am J Physiol Renal Physiol 2005; 288: F253-F264.
15. Nagano N. Pharmacological and clinical properties of calcimimetics: calcium receptor activators that afford an innovative approach to controlling hyperparathyroidism. Pharmacol Ther 2006; 109: 339-365.
16. Levi R, Ben-Dov IZ, Lavi-Moshayoff V et al. Increased parathyroid hormone gene expression in secondary hyperparathyroidism of experimental uremia is reversed by calcimimetics: correlation with posttranslational modification of the trans acting factor AUF1. J Am Soc Nephrol 2006; 17: 107-112.
17. Rodriguez ME, Almaden Y, Canadillas S et al. The calcimimetic R-568 increases vitamin D receptor expression in rat parathyroid glands. Am J Physiol Renal Physiol 2007; 292: F1390-F1395.
18. Goodman WG, Hladik GA, Turner SA et al. The calcimimetic agent AMG 073 lowers plasma parathyroid hormone levels in hemodialysis patients with secondary hyperparathyroidism. J Am Soc Nephrol 2002; 13: 1017-1024.
19. Quarles LD, Sherrard DJ, Adler S et al. The calcimimetic AMG 073 as a potential treatment for secondary hyperparathyroidism of end-stage renal disease. J Am Soc Nephrol 2003; 14: 575-583.
20. Block GA, Martin KJ, de Francisco ALM et al. Cinacalcet for secondary hyperparathyroidism in patients receiving hemodialysis. N Engl J Med 2004; 350: 1516-1525.
21. Moe SM, Chertow GM, Coburn JW et al. Achieving NKF-K//DOQI[trade] bone metabolism and disease treatment goals with cinacalcet HCl. Kidney Int 2005; 67: 760-771.
22. Arenas MD, varez-Ude F, Gil MT et al. Implementation of 'K/DOQI Clinical Practice Guidelines for Bone Metabolism and Disease in Chronic Kidney Disease' after the introduction of cinacalcet in a population of patients on chronic haemodialysis. Nephrol Dial Transplant 2007; 22: 1639-1644.
23. Moe SM, Cunningham J, Bommer J et al. Long-term treatment of secondary hyperparathyroidism with the calcimimetic cinacalcet HCl. Nephrol Dial Transplant 2005; 20: 2186-2193.
24. Chertow GM, Blumenthal S, Turner S et al. Cinacalcet hydrochloride (Sensipar) in hemodialysis patients on active vitamin D derivatives with controlled PTH and elevated calcium x phosphate. Clin J Am Soc Nephrol 2006; 1: 305-312.
25. Messa P, Macario F, Yagoob M et al. The optima study: assessing a new cinacalcet (Sensipar/Mimpara) treatment algorithm for secondary hyperparathyroidism. Clin J Am Soc Nephrol 2008; 3: 36-45.
26. Schaefer RM, Bover J, Kleophas W et al. The sensor study: a study to evaluate the efficacy of administering cinacalcet (Mimpara/Sensipar) with the first meal after dialysis. Nephrol Dial Transplant 2006; 21: IV 288.
27. Alem AM, Sherrard DJ, Gillen DL et al. Increased risk of hip fracture among patients with end-stage renal disease. Kidney Int 2000; 58: 396-399.
28. Jadoul M. Towards the prevention of bone fractures in dialysed patients? Nephrol Dial Transplant 2007; 22: 3377-3380.
29. Wada M, Ishii H, Furuya Y et al. NPS R-568 halts or reverses osteitis fibrosa in uremic rats. Kidney Int 1998; 53: 448-453.
30. Sherrard DJ, Hercz G, Pei Y et al. The spectrum of bone disease in endstage renal failure - an evolving disorder. Kidney Int 1993; 43: 436-442.
31. Mucsi I, Hercz G. Relative hypoparathyroidism and adynamic bone disease. Am J Med Sci 1999; 317: 405-409.
32. Couttenye MM, D'Haese PC, Van Hoof VO et al. Low serum levels of alkaline phosphatase of bone origin: a good marker of adynamic bone disease in haemodialysis patients. Nephrol Dial Transplant 1996; 11: 1065-1072.
33. Spasovski GB, Bervoets ARJ, Behets GJS et al. Spectrum of renal bone disease in end-stage renal failure patients not yet on dialysis. Nephrol Dial Transplant 2003; 18: 1159-1166.
34. Pei Y, Hercz G, Greenwood C et al. Risk factors for renal osteodystrophy: a multivariant analysis. J Bone Miner Res 1995; 10: 149-156.
35. Qi Q, Monier-Faugere MC, Geng Z et al. Predictive value of serum parathyroid hormone levels for bone turnover in patients on chronic maintenance dialysis. Am J Kidney Dis 1995; 26: 622-631.
36. Malluche HH, Monier-Faugere MC. Risk of adynamic bone disease in dialyzed patients. Kidney Int 1992; 38: s62-s67.
37. London GM, Marty C, Marchais SJ et al. Arterial calcifications and bone histomorphometry in end-stage renal disease. J Am Soc Nephrol 2004; 15: 1943-1951.
38. Danese MD, Kim J, Doan OV et al. PTH and the risks for hip, vertebral, and pelvic fractures among patients on dialysis. Am J Kidney Dis 2006; 47: 149-156.
39. Coco M, Rush H. Increased incidence of hip fractures in dialysis patients with low serum parathyroid hormone. Am J Kidney Dis 2000; 36: 1115-1121.
40. Ishii H, Wada M, Furuya Y et al. Daily intermittent decreases in serum levels of parathyroid hormone have an anabolic-like action on the bones of uremic rats with low-turnover bone and osteomalacia. Bone 2000; 26: 175-182.
41. Miller MA, Fox J. Daily transient decreases in plasma parathyroid hormone levels induced by the calcimimetic NPS R-568 slows the rate of bone loss but does not increase bone mass in ovariectomized rats. Bone 2000; 27: 511-519.
42. Kimmel DB, Bozzato RP, Kronis KA et al. The effect of recombinant human (1-84) or synthetic human (1-34) parathyroid hormone on the skeleton of adult osteopenic ovariectomized rats. Endocrinology 1993; 132: 1577-1584.
43. Schmitt CP, Hessing S, Oh J et al. Intermittent administration of parathyroid hormone (1-37) improves growth and bone mineral density in uremic rats. Kidney Int 2000; 57: 1484-1492.
44. Malluche HH, Monier-Faugere MC, Wang G et al. Cinacalcet HCl reduces bone turnover and bone marrow fibrosis in hemodialysis patients with secondary hyperparathryoidism. Nephrol Dial Transplant 2004; 2004: M016.
45. Lien YH, Silva AL, Whittman D. Effects of cinacalcet on bone mineral density in patients with secondary hyperparathyroidism. Nephrol Dial Transplant 2005; 20: 1232-1237.
46. Cunningham J, Danese M, Olson K et al. Effects of the calcimimetic cinacalcet HCl on cardiovascular disease, fracture, and health-related quality of life in secondary hyperparathyroidism. Kidney Int 2005; 68: 1793-1800.
47. Block GA, Raggi P, Bellasi A et al. Mortality effect of coronary calcification and phosphate binder choice in incident hemodialysis patients. Kidney Int 2007; 71: 438-441.
48. Blacher J, Guerin AP, Pannier B et al. Arterial calcifications, arterial stiffness, and cardiovascular risk in end-stage renal disease. Hypertension 2001; 38: 938-942.
49. Wang AYM, Wang M, Woo J et al. Cardiac valve calcification as an important predictor for all-cause mortality and cardiovascular mortality in long-term peritoneal dialysis patients: a prospective study. J Am Soc Nephrol 2003; 13: 159-168.
50. London GM, Guerin AP, Marchais SJ et al. Arterial media calcification in end-stage renal disease: impact on all-cause and cardiovascular mortality. Nephrol Dial Transplant 2003; 18: 1731-1740.
51. Giachelli CM. Vascular calcification mechanisms. J Am Soc Nephrol 2004; 15: 2959-2964.
52. Neves KR, Graciolli FG, dos Reis LM et al. Vascular calcification: contribution of parathyroid hormone in renal failure. Kidney Int 2007; 71: 1262-1270.
53. Guerin AP, London GM, Marchais SJ et al. Arterial stiffening and vascular calcifications in end-stage renal disease. Nephrol Dial Transplant 2000; 15: 1014-1021.
54. Goodman WG, Goldin J, Kuizon BD et al. Coronary-artery calcification in young adults with end-stage renal disease who are undergoing dialysis. N Engl J Med 2000; 342: 1478-1483.
55. Toussaint ND, Lau KK, Strauss BJ et al. Associations between vascular calcification, arterial stiffness and bone mineral density in chronic kidney disease. Nephrol Dial Transplant 2008; 23: 586-593.
56. Raggi P, Bellasi A, Ferramosca E et al. Pulse wave velocity is inversely related to vertebral bone density in hemodialysis patients. Hypertension 2007; 49: 1278-1284.
57. Moe SM, Chertow GM. The case against calcium-based phosphate binders. Clin J Am Soc Nephrol 2006; 1: 697-703.
58. Henley C, Colloton M, Cattley RC et al. 1,25-Dihydroxyvitamin D3 but not cinacalcet HCl (Sensipar(R)/Mimpara(R)) treatment mediates aortic calcification in a rat model of secondary hyperparathyroidism. Nephrol Dial Transplant 2005; 20: 1370-1377.
59. Lopez I, Guilera-Tejero E, Mendoza FJ et al. Calcimimetic R-568 decreases extraosseous calcifications in uremic rats treated with calcitriol. J Am Soc Nephrol 2006; 17: 795-804.
60. Messa P, Alberti L, Como G et al. Calcimimetic increases osteoprotegerin and decreases fetuin-A levels in dialysis patients. Nephrol Dial Transplant 2007; 22: 2724-2725.
61. Goldsmith D, Ritz E, Covic A. Vascular calcification: a stiff challenge for the nephrologist. Kidney Int 2004; 66: 1315-1333.
62. Ketteler M, Bongartz P, Westenfeld R et al. Association of low fetuin-A (AHSG) concentrations in serum with cardiovascular mortality in patients on dialysis: a cross-sectional study. Lancet 2003; 361: 827-833.
63. Kiechl S, Schett G, Wenning G et al. Osteoprotegerin is a risk factor for progressive atherosclerosis and cardiovascular disease. Circulation 2004; 109: 2175-2180.
64. Mehrotra R, Westenfeld R, Christenson P et al. Serum fetuin-A in nondialyzed patients with diabetic nephropathy: relationship with coronary artery calcification. Kidney Int 2005; 67: 1070-1077.
65. Ogata H, Ritz E, Odoni G et al. Beneficial effects of calcimimetics on progression of renal failure and cardiovascular risk factors. J Am Soc Nephrol 2003; 14: 959-967.
66. Odenwald T, Nakagawa K, Hadtstein C et al. Acute blood pressure effects and chronic hypotensive action of calcimimetics in uremic rats. J Am Soc Nephrol 2006; 17: 655-662.
67. Evenepoel P, Claes K, Kuypers D et al. Impact of parathyroidectomy on renal graft function, blood pressure and serum lipids in kidney transplant recipients: a single centre study. Nephrol Dial Transplant 2005; 20: 1714-1720.
68. Jorde R, Svartberg J, Sundsfjord J. Serum parathyroid hormone as a predictor of increase in systolic blood pressure in men. J Hypertens 2005; 23: 1639-1644.
69. Nyirenda MJ, Padfield PL. Parathyroid hormone and hypertension. J Hypertens 2005; 23: 1633-1634.
70. Lindberg JS. Calcimimetics: a new tool for management of hyperparathyroidism and renal osteodystrophy in patients with chronic kidney disease. Kidney Int 2005; 67: s33-s36.
71. Akmal M, Kasim SE, Soliman AR et al. Excess parathyroid hormone adversely affects lipid metabolism in chronic renal failure. Kidney Int 1990; 37: 854-858.
72. Klin M, Smogorzewski M, Ni Z et al. Abnormalities in hepatic lipase in chronic renal failure. Role of excess parathyroid hormone. J Clin Invest 1996; 97: 2167-2173.
73. Roullet JB, Lacour B, Yvert JP et al. Correction by insulin of disturbed TG-rich LP metabolism in rats with chronic renal failure. Am J Physiol Endocrinol Metab 1986; 250: E373-E376.
74. Chertow GM, Pupim LB, Block GA et al. Evaluation of cinacalcet therapy to lower cardiovascular events (EVOLVE): rationale and design overview. Clin J Am Soc Nephrol 2007; 2: 898-905.
75. Wanner C, Krane V, Marz W et al. Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis. N Engl J Med 2005; 353: 238-248.
76. Besarab A, Bolton WK, Browne JK et al. The effects of normal as compared with low hematocrit values in patients with cardiac disease who are receiving hemodialysis and epoetin. N Engl J Med 1998; 339: 584-590.
77. Eknoyan G, Beck GJ, Cheung AK et al. Effect of dialysis dose and membrane flux in maintenance hemodialysis. N Engl J Med 2002; 347: 2010-2019.
78. Suki WN, Zabaneh R, Cangiano JL et al. Effects of sevelamer and calcium-based phosphate binders on mortality in hemodialysis patients. Kidney Int 2007; 72: 1130-1137.
79. Craver L, Marco MP, Martinez I et al. Mineral metabolism parameters throughout chronic kidney disease stages 1-5 - achievement of K/DOQI target ranges. Nephrol Dial Transplant 2007; 22: 1171-1176.
80. Gutierrez O, Isakova T, Rhee E et al. Fibroblast growth factor-23 mitigates hyperphosphatemia but accentuates calcitriol deficiency in chronic kidney disease. J Am Soc Nephrol 2005; 16: 2205-2215.
81. Levin A, Bakris GL, Molitch M et al. Prevalence of abnormal serum vitamin D, PTH, calcium, and phosphorus in patients with chronic kidney disease: results of the study to evaluate early kidney disease. Kidney Int 2007; 71: 31-38.
82. Berndt T, Kumar R. Phosphatonins and the regulation of phosphate homeostasis. Annu Rev Physiol 2007; 69: 341-359.
83. Liu S, Quarles LD. How fibroblast growth factor 23 works. J Am Soc Nephrol 2007; 18: 1637-1674.
84. Shigematsu T, Kazama J, Yamamashita T et al. Possible involvement of circulating fibroblast growth factor 23 in the development of secondary hyperparathyroidism associated with renal insufficiency. Am J Kidney Dis 2004; 44: 250-256.
85. Shimada T, Hasegawa H, Yamazaki Y et al. FGF-23 is a potent regulator of vitamin D metabolism and phosphate homeostasis. Bone Miner Res 2004; 19: 429-435.
86. Coburn JW, Popovtzer M, Massry SG et al. The physicochemical state and renal handling of divalent ions in chronic renal failure. Arch Int Med 1969; 124: 302-311.
87. Coburn JW, Koppel MH, Brickman AS et al. Study of intestinal absorption of calcium in patients with renal failure. Kidney Int 1973; 3: 264-272.
88. Popovtzer MM, Schainuck LJ, Massry SG et al. Divalent ion excretion in chronic kidney disease: relation to degree of renal insufficiency. Clin Sci 1970; 38: 297-307.
89. Goodman WG, Quarles LD. Development and progression of secondary hyperparathyroidism in chronic kidney disease: lessons from molecular genetics. Kidney Int 2008; advance online publication 13 June 2007; doi:10.1038/sj/ki.5002287.
90. Slatopolsky E, Bricker NS. The role of phosphorus restriction in the prevention of secondary hyperparathyroidism in chronic renal disease. Kidney Int 1973; 4: 141-145.
91. Charytan C, Coburn JW, Chonchol M et al. Cinacalcet hydrochloride is an effective treatment for secondary hyperparathyroidism in patients with CKD not receiving dialysis. Am J Kidney Dis 2005; 46: 58-67.
92. Serra AL, Savoca R, Huber AR et al. Effective control of persistent hyperparathyroidism with cinacalcet in renal allograft recipients. Nephrol Dial Transplant 2007; 22: 577-583.
93. Shigematsu T, Caverzasio J, Bonjour J. Parathyroid removal prevents the progression of chronic renal failure induced by high protein diet. Kidney Int 1993; 44: 173-181.
94. Massfelder T, Parekh N, Endlich K et al. Effect of intrarenally infused parathyroid hormone-related protein on renal blood flow and glomerular filtration rate in the anaesthetized rat. Br J Pharmacol 1996; 118: 1995-2000.
95. Lau K. Phosphate excess and progressive renal failure: the precipitation-calcification hypothesis. Kidney Int 1989; 36: 918-937.
96. Khan SR. Crystal-induced inflammation of the kidneys: results from human studies, animal models, and tissue-culture studies. Clin Exp Nephrol 2004; 8: 75-88.
97. Pattaragarn A, Fox J, Alon US. Effect of the calcimimetic NPS R-467 on furosemide-induced nephrocalcinosis in the young rat. Kidney Int 2004; 65: 1684-1689.
98. Kohlhagen J, Kelly J. Prevalence of vascular risk factors and vascular disease in predialysis chronic renal failure. Nephrology (Carlton) 2003; 8: 274-279.
99. Kestenbaum B, Sampson JN, Rudser KD et al. Serum phosphate levels and mortality risk among people with chronic kidney disease. J Am Soc Nephrol 2005; 16: 520-528.
100. Voormolen N, Noordzij M, Grootendorst DC et al. High plasma phosphate as a risk factor for decline in renal function and mortality in pre-dialysis patients. Nephrol Dial Transplant 2007; 22: 2909-2916.
101. Urakawa I, Yamazaki Y, Shimada T et al. Klotho converts canonical FGF receptor into a specific receptor for FGF23. Nature 2006; 444: 770-774.
102. Kuro-o M. Klotho as a regulator of fibroblast growth factor signaling and phosphate/calcium metabolism. Curr Opin Nephrol Hypertens 2006; 15: 437-441.
103. Morishita K, Shirai A, Kubota M et al. The progression of aging in Klotho mutant mice can be modified by dietary phosphorus and zinc. J Nutr 2001; 131: 3182-3188.
104. Messa P, Sindici C, Cannella G et al. Persistent secondary hyperparathyroidism after renal transplantation. Kidney Int 1998; 54: 1704-1713.
105. Bonarek H, Merville P, Bonarek M et al. Reduced parathyroid functional mass after successful kidney transplantation. Kidney Int 1999; 56: 642-649.
106. Evenepoel P, Naesens M, Claes K et al. Tertiary 'hyperphosphatoninism' accentuates hypophosphatemia and suppresses calcitriol levels in renal transplant recipients. Am J Transplant 2007; 7: 1-8.
107. Evenepoel P, Claes K, Kuypers D et al. Natural history of parathyroid function and calcium metabolism after kidney transplantation: a single-centre study. Nephrol Dial Transplant 2004; 19: 1281-1287.
108. Parfitt A. Hypercalcemic hyperparathyroidism following renal transplantation: differential diagnosis, management, and implications for cell population control in the parathyroid gland. Miner Electrolyte Metab 1982; 8: 92-112.
109. Reinhardt W, Bartelworth H, Jockenhövel F et al. Sequential changes of biochemical bone parameters after kidney transplantation. Nephrol Dial Transplant 1998; 13: 436-442.
110. Ghanekar H, Welch BJ, Moe OW et al. Post-renal transplantation hypophosphatemia: a review and novel insights. Curr Opin Nephrol Hypertens 2006; 15: 97-104.
111. Heaf JG. Bone disease after renal transplantation. Transplantation 2003; 75: 315-325.
112. Sperschneider H, Stein G. Bone disease after renal transplantation. Nephrol Dial Transplant 2003; 18: 874-877.
113. Evenepoel P, Vandenbergh B, Naesens M et al. Parathyroid hormone accentuates hypercalcemia and elevated calcitriol levels in renal transplant recipients in the early posttransplant period. J Am Soc Nephrol 2007; 18: 749A (abstract).
114. Gwinner W, Suppa S, Mengel M et al. Early calcification of renal allografts detected by protocol biopsies: causes and clinical implications. Am J Transplant 2005; 5: 1934-1941.
115. Kruse AE, Eisenberger U, Frey FJ et al. Effect of cinacalcet cessation in renal transplant recipients with persistent hyperparathyroidism. Nephrol Dial Transplant 2007; 22: 2362-2365.
116. Srinivas TR, Schold JD, Womer KL et al. Improvement in hypercalcemia with cinacalcet after kidney transplantation. Clin J Am Soc Nephrol 2006; 1: 323-326.
117. Leca N, Laftavi M, Gundroo A et al. Early and severe hyperparathyroidism associated with hypercalcemia after renal transplant treated with cinacalcet. Am J Transplant 2006; 6: 2391-2395.
118. El-Amm JM, Doshi MD, Singh A et al. Preliminary experience with cinacalcet use in persistent secondary hyperparathyroidism after kidney transplantation. Transplantation 2007; 83: 546-549.
119. Szwarc I, Argiles A, Garrique V et al. Cinacalcet chloride is efficient and safe in renal transplant recipients with posttransplant hyperparathyroidism. Transplantation 2006; 82: 675-680.
120. Bergua C, Torregrosa J-V, Cofan F et al. Cinacalcet for the treatment of hypercalcemia in renal transplanted patients with secondary hyperparathyroidism. Transplant Proc 2007; 39: 2254-2255.
121. Brown EM, Hebert SC. Calcium-receptor-regulated parathyroid and renal function. Bone 1997; 20: 303-309.
122. Falck P, Vethe NT, Asberg A et al. Cinacalcet's effect on the pharmacokinetics of tacrolimus, cyclosporine and mycophenolate in renal transplant recipients. Nephrol Dial Transplant 2008; 23: 1048-1053.
123. Schwarz A, Rustien G, Merkel S et al. Decreased renal transplant function after parathyroidectomy. Nephrol Dial Transplant 2007; 22: 584-591.
124. Evenepoel P, Claes K, Kuypers DR et al. Parathyroidectomy after successful kidney transplantation: a single centre study. Nephrol Dial Transplant 2007; 22: 1730-1737.
125. Thervet E, Legendre C, Beaune P et al. Cytochrome P450 3A polymorphisms and immunosuppressive drugs. Pharmacogenomics J 2005; 6: 37-47.
126. Drueke T, Martin D, Rodriguez M. Can calcimimetics inhibit parathyroid hyperplasia? Evidence from preclinical studies. Nephrol Dial Transplant 2007; 22: 1828-1839.
127. Wada M, Furuya Y, Sakiyama J et al. The calcimimetic compound NPS R-568 suppresses parathyroid cell proliferation in rats with renal insufficiency. Control of parathyroid cell growth via a calcium receptor. J Clin Invest 1997; 100: 2977-2983.
128. Colloton M, Shatzen E, Miller G et al. Cinacalcet HCl attenuates parathyroid hyperplasia in a rat model of secondary hyperparathyroidism. Kidney Int 2005; 67: 467-476.
129. Chin JI, Miller SC, Wada MICH et al. Activation of the calcium receptor by a calcimimetic compound halts the progression of secondary hyperparathyroidism in uremic rats. J Am Soc Nephrol 2000; 11: 903-911.
130. Mizobuchi M, Ogata H, Hatamura I et al. Activation of calcium-sensing receptor accelerates apoptosis in hyperplastic parathyroid cells. Biochem Biophys Res Commun 2007; 362: 11-16.
131. Indridason O, Heath H, Khosla S et al. Non-suppressible parathyroid hormone secretion is related to gland size in uremic secondary hyperparathyroidism. Kidney Int 1996; 50: 1663-1671.
132. McCarron D, Muther RS, Lenfesty B et al. Parathyroid function in persistent hyperparathyroidism: relationship to gland size. Kidney Int 1982; 22: 662-670.
133. Tilling L, Colin Forfar J. Cinacalcet-associated cardiogenic shock in a patient with cardiomyopathy. Clin Ther 2007; 29: 352-356.
134. Iwazu Y, Muto S, Ikeuchi S et al. Reversible hypocalcemic heart failure with T wave alternans and increased QTc dispersion in a patient with chronic renal failure after parathyroidectomy. Clin Nephrol 2006; 65: 65-70.
135. Nowack R, Wachtler P. Hypophosphatemia and hungry bone syndrome in a dialysis patient with secondary hyperparathyroidism treated with cinacalcet - proposal for an improved monitoring. Clin Lab 2006; 52: 583-587.
136. Lazar ES, Stankus N. Cinacalcet-induced hungry bone syndrome. Semin Dial 2007; 20: 83-85.
137. Yajima A, Ogawa Y, Takahashi HE et al. Changes of bone remodeling immediately after parathyroidectomy for secondary hyperparathyroidism. Am J Kidney Dis 2003; 42: 729-738.
138. Cruz DN, Perazella MA. Biochemical aberrations in a dialysis patient following parathyroidectomy. Am J Kidney Dis 1997; 29: 759-762.
139. Miles A-M, Markell MS, Sumrani N et al. Severe hyperparathyroidism associated with prolonged hungry bone syndrome in a renal transplant recipient. J Am Soc Nephrol 1997; 8: 1626-1631.
140. Kumar GN, Sproul C, Poppe L et al. Metabolism and disposition of calcimimetic agent cinacalcet HCl in humans and animal models. Drug Metab Dispos 2004; 32: 1491-1500.
141. Harris RZ, Padhi D, Marburry TC et al. Pharmacokinetics, pharmacodynamics, and safety of cinacalcet hydrochloride in hemodialysis patients at doses up to 200mg once daily. Am J Kidney Dis 2004; 44: 1070-1076.
142. Ohashi N, Uematsu T, Nagashima S et al. The calcimimetic agent KRN 1493 lowers plasma parathyroid hormone and ionized calcium concentrations in patients with chronic renal failure on haemodialysis both on the day of haemodialysis and on the day without haemodialysis. Br J Clin Pharmacol 2004; 57: 726-734.
143. Peacock M, Bilezikian JP, Klassen PS et al. Cinacalcet hydrochloride maintains long-term normocalcemia in patients with primary hyperparathyroidism. J Clin Endocrinol Metab 2005; 90: 135-141.
144. Coen G, Calabria S, Bellinghieri G et al. Parathyroidectomy in chronic renal failure: short- and long-term results on parathyroid function, blood pressure and anemia. Nephron 2001; 88: 149-155.
145. Saunders RN, Karoo R, Metcalfe MS et al. Four gland parathyroidectomy without reimplantation in patients with chronic renal failure. Postgrad Med J 2005; 81: 255-258.
146. Hampl H, Steinmuller T, Frohling P et al. Long-term results of total parathyroidectomy without autotransplantation in patients with and without renal failure. Miner Electrolyte Metab 1999; 25: 161-170.
147. Yajima A, Ogawa Y, Ikehara A et al. Development of low-turnover bone diseases after parathyroidectomy and autotransplantation. Int J Urol 2001; 8: S76-S79.
148. Andress D, Ott S, Maloney N et al. Effect of parathyroidectomy on bone aluminum accumulation in chronic renal failure. N Engl J Med 1985; 312: 468-473.
149. Charhon S, Berland Y, Olmer M et al. Effects of parathyroidectomy on bone formation and mineralization in hemodialyzed patients. Kidney Int 1985; 27: 426-435.
150. Sherrard D, Hercz G, Pei Y et al. The aplastic form of renal osteodystrophy. Nephrol Dial Transplant 1996; 11: 29-31.
151. Stracke S, Jehle PM, Sturm D et al. Clinical course after total parathyroidectomy without autotransplantation in patients with end-stage renal failure. Am J Kidney Dis 1999; 33: 304-311.
152. Yano S, Sugimoto T, Tsukamoto T et al. Effect of parathyroidectomy on bone mineral density in hemodialysis patients with secondary hyperparathyroidism: possible usefulness of preoperative determination of parathyroid hormone level for prediction of bone regain. Horm Metab Res 2003; 35: 259-264.
153. Rudser KD, de Boer IH, Dooley A et al. Fracture risk after parathyroidectomy among chronic hemodialysis patients. J Am Soc Nephrol 2007; 18: 2401-2407.
154. Bleyer A, Burkart J, Piazza M et al. Changes in cardiovascular calcification after parathyroidectomy in patients with ESRD. Am J Kidney Dis 2005; 46: 464-469.
155. Kestenbaum B, Andress DL, Schwartz SM et al. Survival following parathyroidectomy among United States dialysis patients. Kidney Int 2004; 66: 2010-2016.
156. Slinin Y, Foley R, Collins AJ. Clinical epidemiology of parathyroidectomy in hemodialysis patients: the USRDS Waves 1, 3, and 4 Study. Haemodial int 2007; 11: 62-70.
157. Elder GJ. Parathyroidectomy in the calcimimetic era. Nephrology 2005; 10: 511-515.
158. Lomonte C, Antonelli M, Losurdo N et al. Cinacalcet is effective in relapses of secondary hyperparathyroidism after parathyroidectomy. Nephrol Dial Transplant 2007; 22: 2056-2062.
159. Cohen E, Uribarri J. Cinacalcet cost and utility in dialysis patients. Semin Dial 2005; 18: 353-354.
160. Shahapuni I, Monge M, Oprisiu R et al. Drug insight: renal indications of calcimimetics. Nat Clin Pract Nephrol 2006; 2: 316-325.
161. Garside R, Pitt M, Anderson R et al. The cost-utility of cinacalcet in addition to standard care compared to standard care alone for secondary hyperparathyroidism in end-stage renal disease: a UK perspective. Nephrol Dial Transplant 2007; 22: 1428-1436.
162. Narayan R, Perkins RM, Berbano EP et al. Parathyroidectomy versus cinacalcet hydrochloride-based medical therapy in the management of hyperparathyroidism in ESRD: a cost utility analysis. Am J Kidney Dis 2007; 49: 801-813.
163. Shahapuni I, Mansour J, Harbouche L et al. How do calcimimetics fit into the management of parathyroid hormone, calcium, and phosphate disturbances in dialysis patients? Semin Dial 2005; 18: 226-238.
164. Teng M, Wolf M, Lowrie E et al. Survival of patients undergoing hemodialysis with paricalcitol or calcitriol therapy. N Engl J Med 2003; 349: 446-456.
165. Wolf B, Thadhani R. Beyond minerals and parathyroid hormone: role of active vitamin D in end-stage renal disease. Semin Dial 2005; 18: 302-306.
166. Wolf M, Shah A, Gutierrez O et al. Vitamin D levels and early mortality among incident hemodialysis patients. Kidney Int 2007; 72: 1004-1013.
167. Al-Aly Z. Vitamin D as a novel nontraditional risk factor for mortality in hemodialysis patients: the need for randomized trials. Kidney Int 2007; 72: 909-911.
168. Teng M, Wolf M, Ofsthun MN et al. Activated injectable vitamin D and hemodialysis survival: a historical cohort study. J Am Soc Nephrol 2005; 16: 1115-1125.
169. Wang TJ, Pencina MJ, Booth SL et al. Vitamin D deficiency and risk of cardiovascular disease. Circulation 2008; 117: 503-511.
170. Towler DA. Calciotropic hormones and arterial physiology: 'D'-lightful insights. J Am Soc Nephrol 2007; 18: 369-373.